Good evening, this is Markets Desk with your end-of-day briefing.
The Strait of Hormuz is commanding attention across energy and defense markets tonight. Three rounds of American strikes in a single week against Iranian targets, with Central Command reporting three hundred total hits, signals this is no longer a contained skirmish. Analysts are warning an undeclared naval war over the world's most critical oil chokepoint carries serious escalation risk, and crude traders are watching every dispatch.
Shifting to insider activity, and two transactions worth flagging. At Taysha Gene Therapies, the chief research officer sold two hundred thousand shares at a weighted average of six dollars and twenty-four cents, pocketing roughly one point two million dollars after the stock had already surged one hundred forty-nine percent. Insider sales after a run of that magnitude deserve scrutiny, though they don't always signal a fundamental turn.
At Privia Health, former chief executive Shawn Morris exited one hundred thirty-five thousand four hundred ninety-eight shares across two days at the end of June and start of July two thousand twenty-six, generating approximately three point five seven million dollars at around twenty-six dollars and thirty-two cents per share. A departing CEO liquidating at scale is worth watching, though post-tenure sales carry different weight than those of sitting executives.
That's the tape. Markets Desk, signing off the floor.
